Is Annexon, Inc. (ANNX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.8% / 30% | 40.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 3.8% / 33% | 40.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 8.3% / 33% | 89.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.8% / 33% | 40.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 8.3% / 33% | 89.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -84.0% | |
| Return on Assets (ROA) | -45.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$118M |
| Free Cash Flow | -$118M |
| Total Debt | $29M |
| Debt-to-Equity | 16.7 |
| Current Ratio | 4.4 |
| Total Assets | $350M |
Price & Trading
| Last Close | $5.25 |
| 50-Day MA | $5.67 |
| 200-Day MA | $3.84 |
| Avg Volume | 2.6M |
| Beta | 1.2 |
|
52-Week Range
$1.28
| |
About Annexon, Inc. (ANNX)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Annexon, Inc. (ANNX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Annexon, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Annexon, Inc.'s debt ratio?
Annexon, Inc.'s debt ratio is 3.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.3%.
What are Annexon, Inc.'s key financial metrics?
Annexon, Inc. has a market capitalization of $745M. Return on equity stands at -84.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.